The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma

Table 2 Overall survival after resection for pancreatic ductal adenocarcinoma. Univariate survival analysis of 397 patients

Parameter	n	3-year-survival	5-year-survival	p
All	397	29.5 %	18.3 %
Tumor location
Head	336	27.3 %	17.8 %
Distal	61	45.4 %	22.0 %	0.284
Gender
Male	190	29.3 %	15.8 %
Female	207	29.7 %	20.2 %	0.683
Age
> 65 years	225	30.4 %	22.6 %
< 65 years	172	28.3 %	13.8 %	0.493
BMI^a
> 25 kg/m²	161	26.3 %	13.7 %
< 25 kg/m²	235	31.2 %	20.9 %	0.494
Tumor size^a
< 30 mm	223	28.8 %	18.4 %
> 30 mm	157	30.4 %	16.9 %	0.860
Tumor grading^a
Grade 1 + 2	230	29.6 %	18.7 %
Grade 3 + 4	151	26.5 %	15.3 %	0.191
Resection margin^a
R0	283	36.2 %	21.7 %
R+	113	13.5 %	9.9 %	<0.001
Nodal status^a
Negative	121	41.1 %	27.7 %
Positive	272	22.9 %	13.0 %	0.001
Extended resection
None	233	35.9 %	26.1 %
Portal Vein (PV)	133	21.5 %	7.9 %
More than PV, multivisceral	31	12.8 %	0 %	<0.001
PRBC transfusion^a
Yes	143	22.4 %	15.6 %
No	252	33.8 %	19.2 %	0.005
Any complication
Yes	200	31.1 %	17.2 %
No	197	27.8 %	18.7 %	0.916
Surgical complication
Yes	133	37.0 %	18.1 %
No	264	25.9 %	17.4 %	0.149
Adjuvant/additive chemotherapy
Yes/Intended^b	222	37.3 %	14.9 %
No/Unknown	175	22.0 %	15.7 %	0.010

BMI body mass index, PRBC packed red blood cells
^aSome parameters were not available for individual patients (BMI: 1 patient; Tumor size: 17 patients; Tumor grading: 16 patients; Resection margin: 1 patient; Nodal status: 4 patients; PRBC transfusion: 2 patients)
^bIncluded are 22 patients with (additional) neoadjuvant therapy and 62 patients with additive therapy

ISSN: 1471-2482